Purpose: The development of computerized alerts with management strategies for 25 drug-drug interactions (DDIs) is described.
Summary: To ensure that clinicians, when confronted with any of 25 serious DDIs in the ambulatory care setting, can avoid these DDIs while treating patients with appropriate medications, management strategies were developed using a consensus approach. Several methods were used to ensure that the recommended alternatives were truly safe.
Objective: The purpose of this research was to investigate consumer understanding and satisfaction associated with a 3-tier prescription drug benefit among users of the prescription drug benefit.
Methods: This study involved a self-administered postal questionnaire and the use of prescription drug claims to evaluate utilization of prescription medications. Fifteen hundred subjects were randomly selected based on the following inclusion criteria.
Background: Previous research has shown that pharmacoeconomic (PE) data are considered important but may not be optimally utilized by decision makers. No research has compared the effectiveness of different types of PE models.
Objectives: The purpose of this study was to examine the perceived value and understanding of PE models among decision makers in managed care organizations.
Background: Numerous mechanisms have been introduced to deliver prescription drug benefits while controlling pharmaceutical costs. An understanding of the most prominent mechanisms of benefit management is an important step in determining the most effective approach to take in future years.
Objectives: The aims of this review were to illustrate the mechanisms by which managed care has attempted to efficiently and equitably deliver pharmacy benefits and to discuss the impact of such programs, including consumer cost sharing.
Objective: The purpose of this study was to identify patterns of new antidepressant use among children and adolescents and to determine whether the duration of treatment was sufficient.
Methods: A retrospective 12-month analysis was conducted of claims data for a cohort of nine- to 18-year-old new users of antidepressants in an Ohio Medicaid population. Treatment duration was categorized into five time intervals reflecting initial treatment through various continuation periods.